Conferences

November 15, 2024

New study shows IVIG replacement lowers infection risk in CLL and NHL patients, highlighting the need for better IgG testing and IgRT guidelines.

October 22, 2024

Is it safe for relapsed/refractory non-Hodgkin lymphoma patients, including DLBCL, to receive CAR T-cell therapy in an outpatient setting?

October 15, 2024

Dr. Mark Roschewski shared with HealthTree about his presentation at ASH 2023 on the results of a regimen known as ViPOR, designed for patients with R/R DLBCL.

July 16, 2024

Dr. Pierre Bories shared research findings about similarities and differences between older and younger DLBCL patients treated with CAR T-cell therapy.

July 15, 2024

The bispecific antibody epcoritamab (Epkinly) was recently FDA-approved for the treatment of relapsed/refractory follicular lymphoma. Find out more!

July 09, 2024

First results of golcadomide, a new CELMoD, in monotherapy and with rituximab relapsed/refractory follicular lymphoma (non-Hodgkin Lymphoma) by Dr. Chavez.

June 13, 2024

Dr. Jeong Kim shares findings about how the treatment combination of brentuximab vedotin, lenalidomide, and rituximab helps R/R DLBCL patients.

May 27, 2024

The American Society of Clinical Oncology holds a yearly conference in June to allow researchers and doctors in the cancer community an opportunity to share…

May 27, 2024

The American Society of Clinical Oncology holds a yearly conference in June to allow researchers and doctors in the cancer community an opportunity to share…

May 06, 2024

Discover Evorpacept: A Next-Generation CD47 Checkpoint Inhibitor For Cancer Treatment with Enhanced Safety and Efficacy.